Revenue Decline and Cost Management: Arbutus saw a significant drop in revenue, primarily due to decreased license revenue from Qilu Pharmaceutical and lower ONPATTRO royalties from Alnylam.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback